Zobrazeno 101 - 110
of 124
pro vyhledávání: '"Aaron P. Rapoport"'
Publikováno v:
Leukemia. 19:2344-2345
Autor:
Sandra Westphal, Aaron P. Rapoport, Brendan M. Weiss, Sunita Philip, Gwendolyn Binder-Scholl, Helen K. Tayton-Martin, Ribeiro C. Lilliam, Joanna E. Brewer, Naseem Kerr, Ashraf Badros, Dan T. Vogl, Michael Kalos, Dominic P. Smethurst, Alan D. Bennett, Edward A. Stadtmauer, Elizabeth Veloso, Gorgun Akpek, Zhaohui Zheng, Bent K. Jakobsen, Carl H. June, Bruce L. Levine, Nick Pumphrey, Andrew B. Gerry, Holly McConville, Saul Yanovich, Kelly-Marie Betts
Publikováno v:
Blood. 120:472-472
Abstract 472 Background: Despite recent therapeutic advances, multiple myeloma (MM) remains primarily an incurable cancer. Patients experiencing rapid recovery of T cells post auto-SCT may have improved outcomes, and spontaneous cellular responses to
Autor:
Dan T. Vogl, Bruce L. Levine, Ling Cai, Elizabeth Veloso, YinYan Xu, Edward A. Stadtmauer, Zhaohui Zheng, Holly McConville, Sandra Westphal, Aaron P. Rapoport, Brendan M. Weiss, Ashraf Badros, Sunita Philip, Nicole A. Aqui, Andres M. Salazar, Saul Yanovich, Kelly-Marie Betts, Hong-Bin Fang, Scott Strome, Gorgun Akpek, Kathleen Ruehle, Anne Chew, Carl H. June
Publikováno v:
Blood. 120:352-352
Abstract 352 Background: Autologous stem cell transplantation (ASCT) for MM leads to complete responses in ∼20–40% of patients but rare cures. Patients with rapid recovery of T cells post ASCT may have improved outcomes suggesting possible immune
Autor:
Scott A. Kirkley, John F. DiPersio, Aaron P. Rapoport, Neil Blumberg, Jacob M. Rowe, Joanna M. Heal
Publikováno v:
American journal of hematology. 48(2)
To assess the effect of ABO-identical, filtration leukodepleted transfusions on resource consumption and costs of care we performed a cohort study in consecutive adult patients admitted for induction therapy of acute myeloid or lymphoid leukemia duri
Autor:
Ashraf Badros, Saul Yanovich, Olga Goloubeva, Bhavana Bhatnagar, Kathleen Ruehle, Steven Gilmore, Arnold Hoffman, Gorgun Akpek, Aaron P. Rapoport
Publikováno v:
Journal of Clinical Oncology. 30:e19565-e19565
e19565 Background: OM is a common complication of high-dose melphalan in MM patients (pts). Proposed risk factors for OM in SCT include: low albumin and high serum creatinine (Cr) levels, both were evaluated in MM patients undergoing Mel/ASCT. (Grazz
Autor:
Poss Elise Daniela, Fang Hu, Aaron P. Rapoport, Xianfeng Zhao, Hong-Bin Fang, Ronald B. Gartenhaus
Publikováno v:
Blood. 118:1569-1569
Abstract 1569 Background: PBK (PDZ-binding kinase) is a serine-threonine kinase that was originally cloned as an interaction partner with the human tumor suppressor hdlg, as an IL-2 inducible gene in cytotoxic T lymphocytes and as an expressed sequen
Autor:
J. Navarro, Maria Aparecida Zanichelli, Dong-Kee Kim, Jorge Milone, J. E. Cortes, Carlo Gambacorti-Passerini, Nadine Besson, Virginia Kelly, Eric Leip, Hagop M. Kantarjian, Tim H. Brümmendorf, Andrey Zaritskey, Aaron P. Rapoport, Michele Baccarani, Pedro Enrique Dorlhiac-Llacer, Hanna Jean Khoury
Publikováno v:
Journal of Clinical Oncology. 29:6535-6535
6535 Background: BOS is an orally active, dual Src/Abl tyrosine kinase inhibitor (TKI). Methods: This open-label, phase 1/2 trial evaluated safety and efficacy of BOS as 3rd-line therapy in patient...
Autor:
Jane L. Liesveld, Camille N. Abboud, Jacob M. Rowe, M Sherman, R A Duerst, Shirley Eberly, Peter A. Kouides, Charles H. Packman, Martin A. Tanner, Aaron P. Rapoport
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 11(12)
PURPOSE One hundred autotransplants for Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) were examined prospectively to identify variables with prognostic significance. PATIENTS AND METHODS Ninety-six patients with relapsed or refractory HD or
Autor:
Virginia Kelly, Hagop M. Kantarjian, Jorge E. Cortes, H. Jean Khoury, Maria Aparecida Zanichelli, Trevor McMullan, Andrey Zaritskey, Juan Ramon Navarro, Dong-Wook Kim, Pedro Enrique Dorlhiac-Llacer, Andreas Hochhaus, Carlo Gambacorti-Passerini, Aaron P. Rapoport, Nadine Besson
Publikováno v:
Blood. 116:892-892
Abstract 892 Bosutinib (SKI-606) is an orally available, dual Src/Abl tyrosine kinase inhibitor (TKI) with minimal inhibitory activity against PDGFR or c-kit. This open-label, phase 1/2 study evaluated the safety and efficacy of bosutinib as third-li
Publikováno v:
American journal of hematology. 40(2)
Nine patients with relapsed or refractory Hodgkin disease or non-Hodgkin lymphoma underwent peripheral stem cell autografting because of a history of marrow involvement with visible lymphoma. Peripheral stem cells were collected during a process of u